A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), ...

Simtra BioPharma Solutions, a CDMO, formed a five-year strategic alliance with the life science business of Germany-based Merck KGaA, which operates as MilliporeSigma in the U.S. and Canada. The ...

Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic ...

Researchers have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results, the approach combined the benefits of ...

ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put billions ...

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...

CBX-12 targets tumor cells with exatecan, offering potential for patients ineligible for antigen-targeted therapies. Phase 2 trial evaluates CBX-12's safety, tolerability, and efficacy in ...

The pneumococcal conjugate vaccines that were studied were the PCV10 (GSK) and PCV13 (Pfizer). The saccharide in PCV10 is conjugated to nontypable Haemophilus influenzae protein D, tetanus toxoid ...

Credit: Merck. Capvaxive consists of pneumococcal polysaccharides from 21 serotypes, including 8 unique serotypes: 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B. Capvaxive consists of pneumococcal ...